Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Hims and Hers Health Inc (HIMS) Price & Performance

Gilead Sciences, Inc.Trade
Hims and Hers Health IncTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Hims and Hers Health Inc — how do they compare? Gilead Sciences, Inc. trades at $135.49 (market cap $168.35B), while Hims and Hers Health Inc trades at $30.73 (market cap $7.12B). The key difference: Gilead Sciences, Inc. is far larger — about 23.6× Hims and Hers Health Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.

GILDHIMS
Market Cap
$168.35B$7.12B
Sector
HealthHealth
52-Week High
$155.80$62.76
52-Week Low
$110.56$14.52
Enterprise Value
$191.42B$7.82B
Dividend Yield
2.42%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Hims and Hers Health Inc

Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.

Read more on HIMS